Join Growin Stock Community!

高端疫苗6547.TW Overview

TW StockBiotech. & Medical
(No presentation for 6547)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

高端疫苗（6547）Overall Performance

高端疫苗（6547）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

高端疫苗（6547） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

高端疫苗（6547）Key Information

高端疫苗（6547）Profile

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

高端疫苗（6547）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
111.41
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.49%
Net Margin
-27.84%
Revenue Growth (YoY)
-13.93%
Profit Growth (YoY)
-20.33%
3-Year Revenue Growth
-61.55%
3-Year Profit Growth
-56.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
111.41
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
55.49%
Net Margin
-27.84%
Revenue Growth (YoY)
-13.93%
Profit Growth (YoY)
-20.33%
3-Year Revenue Growth
-61.55%
3-Year Profit Growth
-56.52%
default symbol

6547

高端疫苗

35.65D

-1.54%

(-0.02)

  • When is 6547's latest earnings report released?

    The most recent financial report for 高端疫苗 (6547) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6547's short-term business performance and financial health. For the latest updates on 6547's earnings releases, visit this page regularly.

  • What is the operating profit of 6547?

    According to the latest financial report, 高端疫苗 (6547) reported an Operating Profit of -27.58M with an Operating Margin of -13.4% this period, representing a decline of 418.82% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6547's revenue growth?

    In the latest financial report, 高端疫苗 (6547) announced revenue of 205.86M, with a Year-Over-Year growth rate of -15.29%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6547 have?

    At the end of the period, 高端疫苗 (6547) held Total Cash and Cash Equivalents of 198.9M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6547 go with three margins increasing?

    In the latest report, 高端疫苗 (6547) did not achieve the “three margins increasing” benchmark, with a gross margin of 39.94%%, operating margin of -13.4%%, and net margin of -10.98%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6547's profit trajectory and future growth potential.

  • What is the FCF of 6547?

    高端疫苗 (6547)'s Free Cash Flow (FCF) for the period is -22.46M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 581.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.